Free tool
FAERS Monitor: Zymfentra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761358 or its brand name (Zymfentra, Infliximab-Dyyb). Reports on generic versions are filed under their own applications.
Reports
3,446
Serious
2,649
77% of reports
Hospitalization
818
Death reported
93
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- inappropriate schedule of product administration991
- off label use908
- intentional dose omission840
- product dose omission issue448
- overdose320
- suspected off label use311
- weight decreased306
- weight increased306
- therapy interrupted294
- arthralgia288
- fatigue286
- condition aggravated272
- diarrhoea272
- harvey-bradshaw index increased268
- crohn^s disease259
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 12 |
| 2019 | 7 |
| 2020 | 9 |
| 2021 | 25 |
| 2022 | 59 |
| 2023 | 153 |
| 2024 | 382 |
| 2025 | 882 |
| 2026 | 1,915 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| harvey-bradshaw index increasedSignal | 268 | 54571.4 | 37474.0 | 1,466,806 |
| suspected off label useSignal | 311 | 451.2 | 404.1 | 129,690 |
| intentional dose omissionSignal | 840 | 185.3 | 174.5 | 149,430 |
| inappropriate schedule of product administrationSignal | 991 | 33.7 | 32.0 | 31,550 |
| therapy interruptedSignal | 294 | 25.2 | 22.6 | 6,806 |
| product dose omission issueSignal | 448 | 9.3 | 8.5 | 3,357 |
| overdoseSignal | 320 | 9.1 | 8.2 | 2,309 |
| weight increasedSignal | 306 | 8.4 | 7.5 | 1,991 |
| weight decreasedSignal | 306 | 6.7 | 6.0 | 1,495 |
| off label useSignal | 908 | 6.3 | 6.0 | 4,246 |
| condition aggravatedSignal | 272 | 5.5 | 4.9 | 1,001 |
| arthralgiaSignal | 288 | 4.2 | 3.8 | 721 |
| diarrhoeaSignal | 272 | 2.6 | 2.3 | 268 |
| fatigueSignal | 286 | 2.2 | 2.0 | 203 |
| crohn^s disease | 259 | 0.0 | 0.0 | 1,576,079 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.